Recruiting at 1 site Phase 1, Phase 2 Obesity

Obesity study: Semaglutide Pen Injector

Official title Feasibility of Semaglutide in Advanced Lung Disease

ClinicalTrials.gov ID: NCT05746039

What this study is testing

What is Semaglutide Pen Injector?

Semaglutide Pen Injector is an investigational medicine, given as a once-weekly injection under the skin, being studied as a potential treatment for obesity.

Also referred to as Ozempic.

Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The study wants to know if patients with serious lung conditions can tolerate semaglutide and if the drug can be increased to reach a target weight.
Who it's for
Adults who have advanced lung disease such as interstitial lung disease, COPD, sarcoidosis, or pulmonary hypertension and are also overweight or obese.
What's involved
Participants will take semaglutide for 12 weeks, have lung function, physical function and body‑composition tests, and give blood samples before and after treatment. They will also answer surveys about side effects while on the drug.
Time commitment
The trial lasts about 12 weeks and includes two main clinic visits (before and after treatment) plus any additional visits for testing or surveys.
  • Phase 2: a mid-size study of how well it works

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 to 80

You may be able to join if

  • Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary...
  • Age \> 18
  • BMI \> 30 kg/m2
  • Requires supplemental oxygen on exertion
  • Stable treatment regimen X 90 days

You likely can't join if

  • Diabetes
  • Pregnant or Breastfeeding
  • Recent weight loss
  • Recent or chronic GI complaints
  • History of gastroparesis
  • History of scleroderma
See the full eligibility criteria
Who can join
  • Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension
  • Age \> 18
  • BMI \> 30 kg/m2
  • Requires supplemental oxygen on exertion
  • Stable treatment regimen X 90 days
  • Use of disease-modifying therapy
What rules you out
  • Diabetes
  • Pregnant or Breastfeeding
  • Recent weight loss
  • Recent or chronic GI complaints
  • History of gastroparesis
  • History of scleroderma
  • Hospitalized at time of evaluation
  • Use of weight loss medication in last 90 days
  • Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2)
  • Uncontrolled thyroid disease
  • History of acute/chronic pancreatitis
  • Prior suicide attempt
  • Suicidal ideation in last 90 days
  • Presence of a pacemaker or defibrillator

The study team makes the final eligibility decision.

Where it is enrolling

  • Philadelphia, Pennsylvania, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.